We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Magellan (MGLN) Q1 Earnings Top on Lower Medical Utilization
Read MoreHide Full Article
Magellan Health, Inc.’s first-quarter 2020 earnings of $1.15 per share beat the Zacks Consensus Estimate by 69.12% as well as the year-ago bottom line of 40 cents.
Moreover, revenues of $1.79 billion for the quarter ended Mar 31, 2020 surpassed the Zacks Consensus Estimate by 1.61% and also rose 2.9% year over year. The top line trumped the consensus estimate in all the last four quarters.
Segmental profit soared 64% year over year to $74.8 million. The company gained from reduced levels of medical utilization toward the end of March due to a decline in elective services across its healthcare businesses.
Magellan Health Inc Price, Consensus and EPS Surprise
Healthcare segment’s profit of $62.1 million was up 35% year over year, driven by favorable prior-period development and utilization results, particularly in the MCC Magellan Complete Care of Virginia and New York as well as in the reinstatement of the Health Insurer Fee.
Pharmacy Management segment’s profit of $20.9 million skyrocketed 152% year over year on the back of improved gross margins from the company’s PBM business as well a strong performance within its specialty drug management portfolio.
Total costs and expenses rose 5.6% year over year to $1.76 billion due to higher cost of care, direct service costs and other operating expenses plus depreciation and amortization.
Capital Position
Cash flow from operations for the quarter was $31.7 million, down 10.5% year over year.
As of Mar 31, 2020, the company's cash and cash equivalents totaled $383.9 million, up 18% from the level on Dec 31, 2019.
As of Mar 31 2020, total assets of the company increased 4.3% to $3.2 billion from the figure at 2019 end.
Total stockholder's equity inched up 2.4% sequentially to $1.43 billion as of Mar 31, 2020.
2020 Guidance
The company reaffirmed its earlier provided guidance for 2020, which calls for net revenues in the band of $7-$7.4 million, adjusted net income in the range of $83-$103 million, segmental profit between $250 million and $280 million and adjusted EPS in the $3.34-$4.14 bracket.
Business Update
On Apr 30, the company announced the sale of its Magellan Complete Care unit to Molina Healthcare Inc. (MOH - Free Report) for $850 million in cash. Also, the latter entered into multiple long-term agreements with Magellan Health including the purchase of new medical pharmacy and musculoskeletal management services for more than 3 million Molina members and also retained it for behavioral health, radiology and musculoskeletal management services in certain MCC markets.
Among other players in the healthcare industry that already reported earnings, the bottom-line results of UnitedHealth Group Inc. (UNH - Free Report) and Humana Inc. (HUM - Free Report) beat the respective Zacks Consensus Estimate by 2.2% and 11.57%, respectively.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Magellan (MGLN) Q1 Earnings Top on Lower Medical Utilization
Magellan Health, Inc.’s first-quarter 2020 earnings of $1.15 per share beat the Zacks Consensus Estimate by 69.12% as well as the year-ago bottom line of 40 cents.
Moreover, revenues of $1.79 billion for the quarter ended Mar 31, 2020 surpassed the Zacks Consensus Estimate by 1.61% and also rose 2.9% year over year. The top line trumped the consensus estimate in all the last four quarters.
Segmental profit soared 64% year over year to $74.8 million. The company gained from reduced levels of medical utilization toward the end of March due to a decline in elective services across its healthcare businesses.
Magellan Health Inc Price, Consensus and EPS Surprise
Magellan Health Inc price-consensus-eps-surprise-chart | Magellan Health Inc Quote
Healthcare segment’s profit of $62.1 million was up 35% year over year, driven by favorable prior-period development and utilization results, particularly in the MCC Magellan Complete Care of Virginia and New York as well as in the reinstatement of the Health Insurer Fee.
Pharmacy Management segment’s profit of $20.9 million skyrocketed 152% year over year on the back of improved gross margins from the company’s PBM business as well a strong performance within its specialty drug management portfolio.
Total costs and expenses rose 5.6% year over year to $1.76 billion due to higher cost of care, direct service costs and other operating expenses plus depreciation and amortization.
Capital Position
Cash flow from operations for the quarter was $31.7 million, down 10.5% year over year.
As of Mar 31, 2020, the company's cash and cash equivalents totaled $383.9 million, up 18% from the level on Dec 31, 2019.
As of Mar 31 2020, total assets of the company increased 4.3% to $3.2 billion from the figure at 2019 end.
Total stockholder's equity inched up 2.4% sequentially to $1.43 billion as of Mar 31, 2020.
2020 Guidance
The company reaffirmed its earlier provided guidance for 2020, which calls for net revenues in the band of $7-$7.4 million, adjusted net income in the range of $83-$103 million, segmental profit between $250 million and $280 million and adjusted EPS in the $3.34-$4.14 bracket.
Business Update
On Apr 30, the company announced the sale of its Magellan Complete Care unit to Molina Healthcare Inc. (MOH - Free Report) for $850 million in cash. Also, the latter entered into multiple long-term agreements with Magellan Health including the purchase of new medical pharmacy and musculoskeletal management services for more than 3 million Molina members and also retained it for behavioral health, radiology and musculoskeletal management services in certain MCC markets.
Magellan Health carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Among other players in the healthcare industry that already reported earnings, the bottom-line results of UnitedHealth Group Inc. (UNH - Free Report) and Humana Inc. (HUM - Free Report) beat the respective Zacks Consensus Estimate by 2.2% and 11.57%, respectively.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>